Curated News
By: NewsRamp Editorial Staff
April 02, 2026
Soligenix's HyBryte Outperforms Valchlor in CTCL Study with Superior Safety
TLDR
- Soligenix's HyBryte offers a competitive edge with 60% treatment success versus Valchlor's 20% for CTCL, presenting a superior efficacy profile for investors and patients.
- Soligenix's HyBryte demonstrated favorable outcomes in a 12-week comparability study published in Oncology and Therapy, showing no treatment-related adverse events while Valchlor patients experienced multiple reactions.
- HyBryte's potential as a well-tolerated therapy for early-stage CTCL could improve patient quality of life by reducing adverse reactions compared to existing treatments.
- Soligenix's novel photodynamic therapy HyBryte uses safe visible light to treat cutaneous T-cell lymphoma, achieving three times the treatment success rate of Valchlor.
Impact - Why it Matters
This news matters because it represents a significant advancement in treating cutaneous T-cell lymphoma, a rare and often debilitating cancer with limited therapeutic options. HyBryte's demonstrated efficacy and safety profile could offer patients a more effective and tolerable alternative to existing treatments like Valchlor, potentially improving quality of life and outcomes. For the medical community, it highlights progress in photodynamic therapy and rare disease research, while investors may see it as a positive step toward commercialization and market expansion. Additionally, Soligenix's broader pipeline, including vaccines for public health threats, underscores its role in addressing critical healthcare challenges, making this development relevant not just for CTCL patients but for those affected by other rare diseases and infectious risks.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced groundbreaking positive results from a comparability study published in Oncology and Therapy, demonstrating the superior efficacy and safety of its novel photodynamic therapy HyBryte™ (SGX301) compared to Valchlor® for treating cutaneous T-cell lymphoma (CTCL). The study revealed that after 12 weeks, 60% of HyBryte-treated patients achieved treatment success—triple the 20% success rate for Valchlor—with HyBryte showing greater average improvement and, critically, no treatment-related adverse events reported. In stark contrast, Valchlor patients experienced multiple adverse reactions, positioning HyBryte as a potentially well-tolerated therapy for early-stage CTCL, a rare cancer affecting the skin's immune cells. This development is part of Soligenix's Specialized BioTherapeutics business segment, which is advancing HyBryte toward potential worldwide commercialization following successful Phase 3 studies, with expansion into psoriasis also underway.
Beyond CTCL, Soligenix's pipeline includes other innovative programs, such as dusquetide (SGX942) for inflammatory diseases like oral mucositis, and a Public Health Solutions segment focused on vaccines for threats like ricin toxin, filoviruses (e.g., Marburg and Ebola), and COVID-19 via CiVax™, leveraging its proprietary ThermoVax® heat stabilization technology. Supported by government funding from agencies like NIAID, DTRA, and BARDA, the company's work addresses unmet medical needs in rare diseases and public health. The news was disseminated through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which provides extensive distribution and enhancement services to reach investors and the public effectively. For more details, the full press release is available via the provided hyperlink, and updates on SNGX can be found in the company's newsroom, highlighting the broader impact of this breakthrough in oncology and biotechnology.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's HyBryte Outperforms Valchlor in CTCL Study with Superior Safety
